Literature DB >> 7829640

Comparison of the pharmacokinetics of parenteral parathyroid hormone-(1-34) [PTH-(1-34)] and PTH-related peptide-(1-34) in healthy young humans.

L J Fraher1, K Klein, R Marier, D Freeman, G N Hendy, D Goltzman, A B Hodsman.   

Abstract

The amino-terminal fragments of human PTH [hPTH-(1-34)] and PTH-related peptide [PTHrP-(1-34)] appear to be equipotent in several rodent models. However, continuous i.v. infusions of these peptides to young human volunteers suggested that a 10-fold higher molar dose of PTHrP was required to produce comparable circulating levels of the peptide and biochemical responses similar to PTH. As PTHrP has a wide variety of target tissues in mammalian species and may, therefore, play a paracrine, rather than an endocrine, hormonal role in vivo, we evaluated whether enhanced metabolic clearance of injected PTHrP might explain its apparently reduced potency as a PTH-like hormone. Ten healthy subjects [age, 25 +/- 9 (+/- SD) yr] received in random order either hPTH-(1-34) or hPTHrP-(1-34) given by bolus i.v. injections in a dose of 10.7 nmol. Measurements of plasma immunoreactive peptide indicated a comparable volume of distribution for each, but the apparent t1/2 (8.3 +/- 1.6 min) and plasma clearance (4.0 +/- 1.4 L/min) for hPTHrP were significantly (P < 0.05) accelerated compared to those of hPTH (t1/2, 10.2 +/- 0.5 min; clearance, 2.0 +/- 0.4 L/min). Peak plasma cAMP levels were 9-fold lower in response to hPTHrP (29.5 +/- 19 vs. 190 +/- 63 pmol/L; P < 0.01), and increases in urinary cAMP excretion were 5-fold lower (2.1 +/- 1.1 vs. 11.2 +/- 3.7 nmol/mmol creatinine; P < 0.01). No major differences were observed in the urinary excretion of phosphate, calcium, or sodium between the two peptides. Although hPTHrP-(1-34) has a 2-fold higher MCR than hPTH-(1-34), this may not explain the more than 5-fold lower plasma or urinary cAMP response to PTHrP in humans. The comparable effects of PTH and PTHrP on urinary phosphate, calcium, and sodium may indicate a non-cAMP-dependent pathway for these responses, although the intracellular pool of cAMP generated to either peptide, and thus the local target tissue response, could not be estimated in the present study.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7829640     DOI: 10.1210/jcem.80.1.7829640

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

Review 1.  Hormonal and dietary regulation of changes in bone density during lactation and after weaning in women.

Authors:  H J Kalkwarf
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-07       Impact factor: 2.673

Review 2.  PTH and PTHrP effects on the skeleton.

Authors:  A C Karaplis; D Goltzman
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

3.  PTHrP 1-141 and 1-86 increase in vitro bone formation.

Authors:  Blake Eason Hildreth; Jillian L Werbeck; Nandu K Thudi; Xiyun Deng; Thomas J Rosol; Ramiro E Toribio
Journal:  J Surg Res       Date:  2010-03-16       Impact factor: 2.192

4.  Immunohistochemical localization of parathyroid hormone-related protein (PTHrP) and serum PTHrP in normocalcemic patients with oral squamous cell carcinoma.

Authors:  Makoto Tsuchimochi; Ayako Kameta; Mikiko Sue; Masataka Katagiri
Journal:  Odontology       Date:  2005-09       Impact factor: 2.634

5.  O-GlcNAc Engineering of GPCR Peptide-Agonists Improves Their Stability and in Vivo Activity.

Authors:  Paul M Levine; Aaron T Balana; Emmanuel Sturchler; Cassandra Koole; Hiroshi Noda; Barbara Zarzycka; Eileen J Daley; Tin T Truong; Vsevolod Katritch; Thomas J Gardella; Denise Wootten; Patrick M Sexton; Patricia McDonald; Matthew R Pratt
Journal:  J Am Chem Soc       Date:  2019-08-28       Impact factor: 15.419

Review 6.  Optimal dosing and delivery of parathyroid hormone and its analogues for osteoporosis and hypoparathyroidism - translating the pharmacology.

Authors:  Donovan Tay; Serge Cremers; John P Bilezikian
Journal:  Br J Clin Pharmacol       Date:  2017-12-06       Impact factor: 4.335

7.  Generation of Potent and Stable GLP-1 Analogues Via "Serine Ligation".

Authors:  Paul M Levine; Timothy W Craven; Xinting Li; Aaron T Balana; Gregory H Bird; Marina Godes; Patrick J Salveson; Patrick W Erickson; Mila Lamb; Maggie Ahlrichs; Michael Murphy; Cassandra Ogohara; Meerit Y Said; Loren D Walensky; Matthew R Pratt; David Baker
Journal:  ACS Chem Biol       Date:  2022-03-23       Impact factor: 4.634

8.  Prolonged Pharmacokinetic and Pharmacodynamic Actions of a Pegylated Parathyroid Hormone (1-34) Peptide Fragment.

Authors:  Jun Guo; Ashok Khatri; Akira Maeda; John T Potts; Harald Jüppner; Thomas J Gardella
Journal:  J Bone Miner Res       Date:  2016-09-09       Impact factor: 6.741

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.